AU2022374853A1 - Neutralizing monoclonal antibodies against sarbecoviruses - Google Patents

Neutralizing monoclonal antibodies against sarbecoviruses Download PDF

Info

Publication number
AU2022374853A1
AU2022374853A1 AU2022374853A AU2022374853A AU2022374853A1 AU 2022374853 A1 AU2022374853 A1 AU 2022374853A1 AU 2022374853 A AU2022374853 A AU 2022374853A AU 2022374853 A AU2022374853 A AU 2022374853A AU 2022374853 A1 AU2022374853 A1 AU 2022374853A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
chain variable
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022374853A
Other languages
English (en)
Inventor
Massimo Clementi
Nicola CLEMENTI
Elena CRISCUOLO
Martina LIBERA
Nicasio MANCINI
Sofia SISTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ospedale San Raffaele SRL
Original Assignee
Ospedale San Raffaele SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale San Raffaele SRL filed Critical Ospedale San Raffaele SRL
Publication of AU2022374853A1 publication Critical patent/AU2022374853A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022374853A 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against sarbecoviruses Pending AU2022374853A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21205626.1 2021-10-29
EP21205626.1A EP4174083A1 (en) 2021-10-29 2021-10-29 Neutralizing monoclonal antibodies against sarbecoviruses
PCT/IB2022/056706 WO2023073441A1 (en) 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against sarbecoviruses

Publications (1)

Publication Number Publication Date
AU2022374853A1 true AU2022374853A1 (en) 2024-05-16

Family

ID=78414544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022374853A Pending AU2022374853A1 (en) 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against sarbecoviruses

Country Status (6)

Country Link
EP (2) EP4174083A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540147A (cg-RX-API-DMAC7.html)
AU (1) AU2022374853A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235310A1 (cg-RX-API-DMAC7.html)
IL (1) IL312392A (cg-RX-API-DMAC7.html)
WO (1) WO2023073441A1 (cg-RX-API-DMAC7.html)

Also Published As

Publication number Publication date
EP4423124A1 (en) 2024-09-04
JP2024540147A (ja) 2024-10-31
CA3235310A1 (en) 2023-05-04
EP4174083A1 (en) 2023-05-03
IL312392A (en) 2024-06-01
WO2023073441A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
AU2013229488B2 (en) Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
CA2703667A1 (en) Anti-rsv g protein antibodies
CN113150135B (zh) 抗新型冠状病毒受体结合区域中和抗体及其应用
WO2011046623A2 (en) Hiv-1 antibodies
WO2011160083A1 (en) Antibodies useful in passive influenza immuization
JP2013505236A (ja) Ｈｉｖ−１抗体
WO2025246679A1 (zh) 一种广谱中和冠状病毒的抗体及其应用
Chen et al. Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants
CN110483636A (zh) 人源抗HIVgp120特异性抗体Z166及其应用方法
AU2022374853A1 (en) Neutralizing monoclonal antibodies against sarbecoviruses
Pavan et al. Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants
EP4687973A1 (en) Combined antibodies against sarbecoviruses and uses thereof
EP4314045A2 (en) Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
CN121335920A (zh) 靶向HIV Env上的CD4结合位点的广谱中和抗体
CN107383190A (zh) 人源抗HIVgp41特异性抗体及其应用
TW202346329A (zh) 冠狀病毒之特異性抗體及其用途
CN119371521A (zh) 一种广谱抗新型冠状病毒SARS-CoV-2的纳米抗体及其应用
IL278955A (en) Antibodies against sars cov-2
HK1200176B (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
NZ729856B2 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
EP3104884A2 (en) A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection